Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme

Dendritic cell-based cancer immunotherapy targeting MUC-1

Expansion of HIV-specific CD4+ and CD8+ T cells by dendritic cells transfected with mRNA encoding cytoplasm- or lysosome-targeted Nef

HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities

Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions

Dendritic cells expand Epstein Barr virus specific CD8+ T cell responses more efficiently than EBV transformed B cells

Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients

Genetic idiotypic and tumor cell-based vaccine strategies for indolent non Hodgkin’s lymphoma

[In vitro anti-myeloma effects induced by myeloma idiotype-protein pulsed dendritic cell vaccine]